An interventional study of Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation. and Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance. in Paroxysmal Atrial Fibrillation (PAF), sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases — 19 open to participants now, 19 under way, none of them phase 3. Atrial Fibrillation · China National Center for Cardiovascular Diseases.
Among the 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases, this one is the 11th largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2026, is one of 16 with no phase, reaches primary completion later than 17 of the 18 other live ones, and was the 24th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.
Browse Atrial Fibrillation studies →19 of the 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases are open now, in 2 countries. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–85
China National Center for Cardiovascular Diseases · Sites in United States, China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 276 is above the median of 150 across 2,479 interventional studies indexed under Atrial Fibrillation.
Median enrollment 283 across the 20 interventional studies, 265 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
5 of the studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06108414China National Center for Cardiovascular DiseasesLow-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation | 2026-12-31 |
| NCT07146061China National Center for Cardiovascular DiseasespCAD-POAF 3 Year Follow-up | 2027-01 |
| NCT07572253China National Center for Cardiovascular DiseasesA Study of Using CARTO SOUND™ FAM to Guide Pulsed Field Ablation for Atrial Fibrillation | 2027-06-01 |
| NCT07927582China National Center for Cardiovascular DiseasesPulsed Field Ablation for Atrial Fibrillation Under General Anesthesia Versus Remimazolam-based Deep Sedation | 2027-11-30 |
| NCT07601763China National Center for Cardiovascular DiseasesPulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF) | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, randomized, multicenter, open-label, non-inferiority interventional study aims to compare the therapeutic efficacy of percutaneous pulsed field ablation (PFA) guided by ultrasound alone versus fluoroscopy in patients with paroxysmal atrial fibrillation (AF). The success rate of complete electrical isolation of pulmonary veins during the procedure was compared to verify that ultrasound-only guidance is non-inferior to fluoroscopic guidance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.
Procedure: Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.
Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.
Procedure: Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.
Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.
Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.
Success rate of complete electrical isolation of pulmonary veins during the procedure
The proportion of all pulmonary veins maintaining bidirectional block across ablation lines at 20 minutes after ablation completion.
Time frame: Immediately post-procedure
The incidence of complications within 30 days after the procedure
Observe the proportion of complications occurring within 30 days after the procedure. Such complications include pericardial effusion or cardiac tamponade requiring drainage, phrenic nerve palsy lasting more than 24 hours, severe vascular complications requiring intervention, stroke/transient ischemic attack, atrioesophageal fistula, and death.
Time frame: Within 30 days post-procedure
Success rate of atrial fibrillation ablation at 12 months post-procedure.
Defined as the absence of AF, atrial flutter (AFL), or atrial tachycardia (AT) episodes ≥30 seconds on dynamic electrocardiogram (ECG) monitoring after the blanking period (90 days post-catheter ablation)
Time frame: 12 months post-procedure
The proportion of patients admitted to hospital or emergency departments due to atrial fibrillation recurrence within 12 months after the procedure.
The proportion of patients admitted to hospital or emergency departments due to atrial fibrillation recurrence within 12 months after the procedure.
Time frame: 12 months post-procedure
The proportion of patients who received electrical cardioversion due to atrial fibrillation recurrence within 12 months after the procedure
The proportion of patients who received electrical cardioversion due to atrial fibrillation recurrence within 12 months after the procedure.
Time frame: 12 months post-procedure
The proportion of patients undergoing repeat ablation surgery owing to atrial fibrillation within 12 months after the procedure
The proportion of patients undergoing repeat ablation surgery owing to atrial fibrillation within 12 months after the procedure
Time frame: 12 months post-procedure
The proportion of patients who resumed antiarrhythmic drug therapy during follow-up after the blanking period
The proportion of patients who resumed antiarrhythmic drug therapy during follow-up after the blanking period
Time frame: From the end of the blanking period (within 90 days after catheter ablation) to 12 months post-procedure
Improvement in the total EQ-5D quality-of-life questionnaire score at 12 months post-procedure compared with baseline
The degree of improvement in total EQ-5D scores at 12 months after ablation relative to baseline levels
Time frame: 12 months post-procedure
Statistical analysis was performed to evaluate differences in fluoroscopic exposure dose between the two groups.
Statistical analysis was performed to evaluate differences in fluoroscopic exposure dose between the two groups.
Time frame: Immediately post-procedure
Compare the length of hospital stay and postprocedural ICU/CCU stay duration between the two groups.
After hospital discharge, the length of hospital stay for this admission and the duration of postoperative observation in CCU/ICU were compared between the two groups of patients.
Time frame: through study completion, an average of 1 year
Compare the procedural time and DSA fluoroscopy time between the two groups.
Statistical analyses were performed to compare procedural duration and DSA fluoroscopy duration across the two groups.
Time frame: Immediately post-procedure
Compare the differences in costs between the two groups, including medical equipment costs, personnel costs, and patient hospitalization expenses.
Total hospitalization costs incurred during this admission were compared between the two groups after hospital discharge.
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Feb 2029, 29 months after the start.
Of 794 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 29 months is below that.
Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →